ATE402140T1 - Cyclopentyl sulfonamid derivaten - Google Patents

Cyclopentyl sulfonamid derivaten

Info

Publication number
ATE402140T1
ATE402140T1 AT00978244T AT00978244T ATE402140T1 AT E402140 T1 ATE402140 T1 AT E402140T1 AT 00978244 T AT00978244 T AT 00978244T AT 00978244 T AT00978244 T AT 00978244T AT E402140 T1 ATE402140 T1 AT E402140T1
Authority
AT
Austria
Prior art keywords
sulfonamide derivatives
cyclopentyl sulfonamide
cyclopentyl
mammal
useful
Prior art date
Application number
AT00978244T
Other languages
English (en)
Inventor
James Aikins
Edward Smith
Timothy Shepherd
Dennis Zimmerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE402140T1 publication Critical patent/ATE402140T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/04—Diamides of sulfuric acids
    • C07C307/08—Diamides of sulfuric acids having nitrogen atoms of the sulfamide groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00978244T 1999-12-08 2000-11-03 Cyclopentyl sulfonamid derivaten ATE402140T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16968499P 1999-12-08 1999-12-08
US21428300P 2000-06-26 2000-06-26

Publications (1)

Publication Number Publication Date
ATE402140T1 true ATE402140T1 (de) 2008-08-15

Family

ID=26865281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00978244T ATE402140T1 (de) 1999-12-08 2000-11-03 Cyclopentyl sulfonamid derivaten

Country Status (6)

Country Link
EP (1) EP1246797B1 (de)
AT (1) ATE402140T1 (de)
AU (1) AU1572301A (de)
DE (1) DE60039631D1 (de)
ES (1) ES2307537T3 (de)
WO (1) WO2001042203A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9702194D0 (en) 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
WO2002032858A1 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Cycloalkylfluorosulfonamide derivatives
AU2002307327A1 (en) * 2001-05-04 2002-11-18 Eli Lilly And Company Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
GB0417709D0 (en) * 2004-08-09 2004-09-08 Glaxo Group Ltd Compounds
US7411093B2 (en) 2004-12-20 2008-08-12 Hoffman-La Roche Inc. Aminocycloalkanes as DPP-IV inhibitors
DE602006003661D1 (de) 2005-06-06 2008-12-24 Lilly Co Eli Ampa-rezeptoren-verstärker
JP5014334B2 (ja) * 2005-10-06 2012-08-29 イーライ リリー アンド カンパニー Ａｍｐａ受容体増強剤
GB0602560D0 (en) * 2006-02-08 2006-03-22 Glaxo Group Ltd Compounds
JP2010517926A (ja) * 2006-02-08 2010-05-27 グラクソ グループ リミテッド グルタミン酸受容体を増強する、統合失調症の治療に有用な４−フェニル−３−（２−プロピルスルホニルアミノ）テトラヒドロフラン誘導体
US8669291B2 (en) * 2007-05-31 2014-03-11 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
US20130109714A1 (en) * 2010-03-26 2013-05-02 National University Corporation Hokkaido University Neurodegenerative disease therapeutic agent
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
JP2002504502A (ja) * 1998-02-24 2002-02-12 イーライ・リリー・アンド・カンパニー スルホンアミド誘導体

Also Published As

Publication number Publication date
EP1246797A1 (de) 2002-10-09
DE60039631D1 (de) 2008-09-04
AU1572301A (en) 2001-06-18
ES2307537T3 (es) 2008-12-01
EP1246797B1 (de) 2008-07-23
WO2001042203A1 (en) 2001-06-14

Similar Documents

Publication Publication Date Title
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
PT1007523E (pt) Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
NL300877I2 (nl) obeticholzuur
BG66085B1 (bg) Фенилаланинови производни
DE60204674D1 (de) Retinoid x rezeptormodulatoren
SE9904505D0 (sv) Novel compounds
TR200100137T2 (tr) Obesitenin ve başka bozuklukların tedavisinde yararlı nöropeptit Y Y5 reseptörü için ligandlar olarak N-ikameli aminotetralinler.
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
TR200102338T2 (tr) Siklik ikame edilmiş bağlı pirolokarbazoller ve izoindolonlar.
TR199800436A2 (xx) Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�.
ATE402140T1 (de) Cyclopentyl sulfonamid derivaten
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
DE60031886D1 (de) Purinderivate
DE69917278D1 (de) Heterocyclyl sulphonamid derivate
BR0112043A (pt) Ftalidas substituìdas, processo para sua preparação e composições farmacêuticas contendo-as
TR200200125T2 (tr) Yeni aminotiyazol türevleri, bunların hazırlanması ve bunları içeren farmasötik kompozisyonlar.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
CY1105798T1 (el) Στepοειδη, η παρασκευη τους, φαρμακευτικες συνθεσεις απο αυτα και χρησεις των ενωσεων
TR199901380A2 (xx) Di-ya da triazo-spiro$4,5] dekan t�revleri
EA200201024A1 (ru) Фармацевтические композиции, содержащие олигосахариды, и их получение
ATE229934T1 (de) Sulfonamid-derivate
TR200002293T2 (tr) Farmasötik bileşimler.
MXPA04003297A (es) Derivados novedosos de benzotiacina su preparacion y uso.
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE59803066D1 (de) Substituierte benzyloxyimino-verbindungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties